These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 32508018)

  • 21. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.
    Mercogliano MF; Bruni S; Mauro F; Elizalde PV; Schillaci R
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploiting innate immunity for cancer immunotherapy.
    Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
    Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer.
    Silverio KA; Patel SA
    Oncol Lett; 2017 Apr; 13(4):2015-2020. PubMed ID: 28454356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell transfer for cancer immunotherapy.
    Zhao L; Zhang S; Kepp O; Kroemer G; Liu P
    Int Rev Cell Mol Biol; 2022; 370():33-64. PubMed ID: 35798506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
    Chyuan IT; Chu CL; Hsu PN
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
    Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
    Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.
    Li D; Cao D; Sun Y; Cui Y; Zhang Y; Jiang J; Cao X
    Front Immunol; 2024; 15():1331641. PubMed ID: 38348027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.